Rain Therapeutics
Developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 -8.9x EV/EBITDA | round | |
* | $50.0m | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Rain Therapeutics is a biotechnology company focused on developing targeted therapies for cancer patients. The company identifies cancers with a single, clear oncogenic driver and evaluates subpopulations of cancer patients with unmet needs where current standards of care are ineffective. Utilizing a global network of scientific and thought leaders, Rain Therapeutics matches these cancers with small molecule therapeutics designed to treat specific cancer mutations. The company's lead program, tarloxotinib, is a hypoxia-activated prodrug aimed at treating cancers with specific genetic mutations. Rain Therapeutics primarily serves patients with cancer, operating within the oncology market. The business model involves the development and commercialization of proprietary cancer therapies, generating revenue through the sale of these specialized treatments.
Keywords: targeted therapies, cancer, oncogenic driver, unmet needs, small molecule therapeutics, tarloxotinib, hypoxia-activated, biotechnology, oncology, genetic mutations.